This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): R83842, Rivizor
Description: Vorozole is a novel aromatase inhibitor. Aromatase inhibitors act by blocking the synthesis of oestrogen and early tests indicate vorozole's potential to improve ovulation.
Deal Structure: In February 2005, Ferring Pharmaceuticals announced that it signed an agreement with Metris Therapeutics for all potential infertility indications of the compound vorozole. Under the agreement Ferring has the rights to manufacture, develop, register and market vorozole in ovulation induction and in-vitro fertilisation (IVF).Vorozole had been in development for breast cancer by Janssen, but details on licensing arrangements are not available.
Pink Sheet In Brief: J&J's Rivizor
Pink Sheet In Brief: Janssen Rivizor
Additional information available to subscribers only: